CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer. Seitz S, Dreyer TF, Stange C, Steiger K, et al. Br J Cancer 2022 Mar 21. pii: 10.1038/s41416-022-01763.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Seitz S, Dreyer TF, Stange C, Steiger K, et al. CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer. Br J Cancer 2022 Mar 21. pii: 10.1038/s41416-022-01763.
PMID: 35314795